A potential outcomes-based pricing scheme from bluebird bio Inc. (NASDAQ:BLUE) for its gene therapy could resonate with payers and proffer tentative solutions for navigating challenges around outcome tracking, patient portability and the Medicaid best price rule.
Under the model, presented Tuesday at the J.P. Morgan Healthcare Conference, payers would make up to five equal payments for LentiGlobin BB305 across five years, with 80% of the
